IRIS Accounts Production v24.1.4.33 12523335 Board of Directors 1.1.23 31.12.23 31.12.23 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh125233352022-12-31125233352023-12-31125233352023-01-012023-12-31125233352021-12-31125233352022-01-012022-12-31125233352022-12-3112523335ns15:EnglandWales2023-01-012023-12-3112523335ns14:PoundSterling2023-01-012023-12-3112523335ns10:Director12023-01-012023-12-3112523335ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3112523335ns10:SmallEntities2023-01-012023-12-3112523335ns10:AuditExempt-NoAccountantsReport2023-01-012023-12-3112523335ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3112523335ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3112523335ns10:FullAccounts2023-01-012023-12-3112523335ns10:EntityHasNeverTraded2023-01-012023-12-3112523335ns10:OrdinaryShareClass12023-01-012023-12-3112523335ns10:Director32023-01-012023-12-3112523335ns10:RegisteredOffice2023-01-012023-12-3112523335ns5:ShareCapital2023-12-3112523335ns5:ShareCapital2022-12-3112523335ns5:CostValuation2022-12-3112523335ns5:CurrentFinancialInstruments2023-12-3112523335ns5:CurrentFinancialInstruments2022-12-3112523335ns10:OrdinaryShareClass12023-12-31
REGISTERED NUMBER: 12523335 (England and Wales)






















UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31ST DECEMBER 2023

FOR

ELEUSIS THERAPEUTICS HOLDINGS LTD

ELEUSIS THERAPEUTICS HOLDINGS LTD (REGISTERED NUMBER: 12523335)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST DECEMBER 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


ELEUSIS THERAPEUTICS HOLDINGS LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 31ST DECEMBER 2023







DIRECTORS: M J Norris
C B F Mellen





REGISTERED OFFICE: 83 Cambridge Street
Pimlico
London
SW1V 4PS





REGISTERED NUMBER: 12523335 (England and Wales)





ACCOUNTANTS: George Hay & Company
Chartered Accountants
83 Cambridge Street
London
SW1V 4PS

ELEUSIS THERAPEUTICS HOLDINGS LTD (REGISTERED NUMBER: 12523335)

BALANCE SHEET
31ST DECEMBER 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Investments 4 2 2

CURRENT ASSETS
Debtors 5 1 1
NET CURRENT ASSETS 1 1
TOTAL ASSETS LESS CURRENT
LIABILITIES

3

3

CAPITAL AND RESERVES
Called up share capital 6 3 3
SHAREHOLDERS' FUNDS 3 3

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31st December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31st December 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Profit and Loss Account has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 26th July 2024 and were signed on its behalf by:





M J Norris - Director


ELEUSIS THERAPEUTICS HOLDINGS LTD (REGISTERED NUMBER: 12523335)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31ST DECEMBER 2023

1. STATUTORY INFORMATION

Eleusis Therapeutics Holdings Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The company was dormant throughout the current year and previous year.

Preparation of consolidated financial statements
The financial statements contain information about Eleusis Therapeutics Holdings Ltd as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Financial instruments
The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Profit and Loss Account, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 3 (2022 - 3 ) .

ELEUSIS THERAPEUTICS HOLDINGS LTD (REGISTERED NUMBER: 12523335)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31ST DECEMBER 2023

4. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1st January 2023
and 31st December 2023 2
NET BOOK VALUE
At 31st December 2023 2
At 31st December 2022 2

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Amounts owed by group undertakings 1 1

6. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2023 2022
value: £    £   
3 Ordinary £1 3 3

7. ULTIMATE CONTROLLING PARTY AND PARENT UNDERTAKING

The immediate parent undertaking is Eleusis Holdings Limited.

The smallest and largest group for which consolidated financial statements are prepared which include the results of this company is that headed by Eleusis Holdings Limited and these financial statements may be obtained from Beckley Psytech Limited, OX3 9SY.